View PDF Version - RePub - Erasmus Universiteit Rotterdam

Chapter 4.2
200
9.0
8.0
7.0
6.0
5.0
4.0
3.0
log HBV DNA (copies/mL) 10.0
2.0
0
9.0
8.0
7.0
6.0
5.0
4.0
log HBV DNA (copies/mL) 10.0
3.0
2.0
0
9.0
8.0
7.0
6.0
5.0
4.0
log HBV DNA (copies/mL) 10.0
3.0
2.0
0
4
4
4
8 12 16
Time (weeks)
8 12 16
Time (weeks)
8 12
Time (weeks)
16
Patient A
R-RSbd
20
24
log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
4
8 12
Time (weeks)
16
Patient D
R-RSFS
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
Patient F
R-S
20 24
0 4 8 12 16 20 24
Time (weeks)
Patient H
R-RF
20
24
log HBV DNA (copies/mL) 10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
log HBV DNA (copies/mL) 10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
log HBV DNA (copies/mL) 10.0
4
4
8 12
Time (weeks)
16
8 12
Time (weeks)
16
Patient B
F-RS
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
Patient C
F-RFSbd
20 24
0 4 8 12 16 20 24
Time (weeks)
Patient I
R-RSbd
20
Patient K
R-SFSRbd
20
24
24
log HBV DNA (copies/mL) 10.0
9.0
8.0
7.0
6.0
5.0
4.0
log HBV DNA (copies/mL) 10.0
3.0
2.0
0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
log HBV DNA (copies/mL) 10.0
4
4
8 12 16
Time (weeks)
8 12
Time (weeks)
16
Patient G
R-RSF
20
Patient J
R-RSFRbd
Figure 3. Viral decline during 24 weeks of tenofovir therapy in 11 lamivudine-resistant patients who
continued lamivudine treatment. The first-phase was categorized to one of three patterns, according
to the rate of hepatitis B virus (HBV)-DNA decline in the first 4 weeks of treatment: R for rapid declines
of ¼1 log, S for slow declines between 0.5 and 1 log or F for flat declines of 1 log/4 weeks over the 23-week period, S
for slow declines of between 0.2 and 1 log/4 weeks over 23 weeks, F for declines of 1 log. Because of lack of data, patient E is not described. The horizontal straight dotted line is placed
1 log below the initial viral load of the patient; the vertical straight dotted line is placed at the 4-week
time-point.
20
24
24